Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY06006 vs EU-Prolia in postmenopausal women with osteoporosis
2022-002312-23Phase 3Active
- Sponsor
- Boan Biotech
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CMAB807 in osteoporosis (2 arms), sponsored by Boan Biotech. Started Nov 2022; status: active.
02
Drugs
CMAB807
03
Conditions
osteoporosis
Beyond the preview
Go deeper on 2022-002312-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002312-23.